Allergy & Immunology
Latest news
86 articles · 20 / page
Five-Year Ublituximab Treatment Shows Sustained Benefits in Relapsing Multiple Sclerosis: ULTIMATE Extension Study
Long-term data from the ULTIMATE open-label extension study demonstrates sustained efficacy and safety of ublituximab in relapsing multiple sclerosis over five years, with significant reductions in relapse rates and disability progression c
Institutional Policy Shifts on Penicillin Allergy Labels Dramatically Increase Cefuroxime Use in Cataract Surgery
A large-scale quality improvement study reveals that reclassifying penicillin allergies and providing pharmacy support can increase the use of intracameral cefuroxime from 2% to over 70%, significantly improving evidence-based prophylaxis i
Sopoongsan Attenuates Chronic Pruritus via STAT1 Inhibition: Evidence from a Randomized Pilot Trial and Translational Models
A pilot randomized controlled trial and translational study demonstrate that Sopoongsan (SPS) effectively reduces chronic upper body pruritus in atopic and seborrheic dermatitis by inhibiting STAT1-mediated inflammatory pathways, offering a
Pumecitinib 3% Gel Shows Robust Efficacy and Minimal Systemic Absorption in Mild-to-Moderate Atopic Dermatitis Treatment
A Phase IIb clinical trial demonstrates that pumecitinib 3% gel significantly improves skin clearance in adults with mild-to-moderate atopic dermatitis. Twice-daily application proved superior to once-daily dosing, maintaining a favorable s
Beyond the Primary Endpoint: High-Dose Vilobelimab Demonstrates Clinical Utility in Reducing Draining Tunnels in Hidradenitis Suppurativa
The SHINE trial, despite missing its primary endpoint due to a high placebo response, suggests that high-dose vilobelimab significantly reduces draining tunnels in moderate-to-severe hidradenitis suppurativa, offering a potential new therap
Beyond Th2: Single-Dose Aletekitug Targets IL-18 to Deliver Sustained Clinical and Molecular Remission in Atopic Dermatitis
A phase 1/2 study reveals that a single dose of aletekitug, an anti-IL-18 antibody, provides durable clinical improvement and broad molecular modulation in moderate-to-severe atopic dermatitis, targeting pathways beyond traditional Type 2 i
Baricitinib Demonstrates Superior Efficacy Over Azathioprine in Adults with Moderate-to-Severe Atopic Dermatitis: Results from a Randomized Head-to-Head Trial
A randomized trial (NCT05969730) shows that baricitinib plus topical corticosteroids significantly outperformed azathioprine in achieving EASI 75 at 12 weeks (65% vs. 15%) in patients with moderate-to-severe atopic dermatitis, with both tre
Antenatal Prebiotic Supplementation Fails to Prevent Atopic Dermatitis in High-Risk Infants: Insights from the PREGRALL Trial
The multicenter PREGRALL trial demonstrates that maternal intake of galacto-oligosaccharide/inulin prebiotics from mid-gestation does not reduce the incidence of atopic dermatitis or allergic sensitization in high-risk infants by age one, c
Mapping Multimorbidity in Severe Asthma: Defining Replicable Phenotypes to Optimize Personalized Care
This review analyzes findings from the pan-European SHARP registry study, identifying distinct multimorbidity phenotypes in severe asthma. It highlights the impact of steroid-associated and sinonasal clusters on clinical outcomes, advocatin
Targeted HEV Modulation: A Novel Antibody-Drug Conjugate Strategy to Overcome Cardiac Allograft Rejection
Researchers have developed a first-in-class antibody-drug conjugate targeting High Endothelial Venules via the CHST4 enzyme. This therapy promotes regulatory T cell induction and long-term heart transplant survival in murine models using si
Bridging the Gap: A New Evidence-Based Patient Decision Aid for Systemic Atopic Dermatitis Therapy
Researchers have developed the first Patient Decision Aid (PDA) specifically for adult systemic atopic dermatitis treatments. The study highlights a ‘staged approach’ that balances clinician-driven data requirements with patient-preferred s
Beyond Antihistamines: Dupilumab Emerges as a Potent Strategy for Refractory Chronic Spontaneous Urticaria
The Phase 3 LIBERTY-CSU CUPID trials demonstrate that dupilumab significantly reduces itch and hives in patients with chronic spontaneous urticaria uncontrolled by antihistamines, providing a crucial new therapeutic option for those who are
Tezepelumab Enables Complete Oral Corticosteroid Discontinuation in 50% of Patients with Severe, Uncontrolled Asthma: Results from the WAYFINDER Phase 3b Trial
The WAYFINDER study reveals that tezepelumab significantly reduces OCS dependence in severe asthma, with over half of patients achieving complete discontinuation by week 52 while maintaining asthma control, regardless of baseline inflammato
Redefining Reliever Therapy: Budesonide-Formoterol Outperforms SABA in Controlling Airway Inflammation Among Patients on Maintenance Corticosteroids
The INFORM ASTHMA trial demonstrates that budesonide-formoterol as a reliever significantly reduces Type 2 airway inflammation (FeNO) compared to terbutaline in adults already using maintenance inhaled corticosteroids, establishing a new ev
Paracetamol vs. Ibuprofen in Infancy: The PIPPA Tamariki Trial Finds No Differential Risk for Eczema or Bronchiolitis
The PIPPA Tamariki randomized controlled trial demonstrates that using paracetamol versus ibuprofen as needed in the first year of life does not significantly alter the risk of developing eczema or bronchiolitis by age one, challenging long
Mapping the Atopic Landscape: New Meta-Analysis Identifies Key Drivers and Critical Windows for Childhood Food Allergy
This comprehensive systematic review and meta-analysis of 190 studies involving 2.8 million participants establishes a 4.7% incidence rate for childhood food allergy and identifies early atopic conditions, microbiome disruptions, and delaye
High-Dose Prenatal Vitamin D and Childhood Atopy: Why Maternal Smoking History Matters
Recent findings from the COPSAC2010 trial and EDEN cohort suggest that high-dose prenatal vitamin D’s protective effect against atopic dermatitis is significantly enhanced in children of mothers exposed to tobacco, highlighting a potential
Engineering a Cure: How CAR T-Cell Therapy is Transforming the Fight Against Autoimmune Hemolytic Anemia
A groundbreaking study shows that CD19 CAR T-cell therapy can induce sustained, drug-free remission in patients with severe, multirefractory autoimmune hemolytic anemia by successfully eliminating the autoreactive B-cells that drive the dis
IL-13 Inhibition with Cendakimab: A New Frontier in Eosinophilic Esophagitis Management
A Phase 3 trial demonstrates that cendakimab significantly reduces dysphagia days and improves histologic and endoscopic markers in patients with eosinophilic esophagitis, offering a targeted therapeutic approach for this chronic type 2 inf
“Off-the-Shelf” Allogeneic Regulatory T-Cell Therapy Shows Safety and Slows Functional Decline in ALS
A Phase 1 trial published in NEJM Evidence demonstrates that allogeneic, umbilical cord-derived regulatory T cells are safe and potentially effective in slowing the progression of ALS, providing a scalable, off-the-shelf alternative to trad
Browse by specialty
Open language-specific specialty feeds and department pages.